Archivel Farma's TB Vaccine May Cut Treatment Time From Nine Months to One

BIO CONVENTION, CHICAGO, Illinois, May 5, 2010 - Archivel Farma, S.L. has announced that its breakthrough
treatment for tuberculosis (TB) will shortly start phase II clinical trials.
The treatment uses the company's unique combination of its novel therapeutic
vaccine called RUTI(R) in conjunction with an antibiotic. This cuts treatment
time from nine months to one month, which reduces side effects and healthcare
costs, by preventing re-infection during the eradication process. The company
expects commercial availability in 2015.

It has now been discovered that TB does not lie "dormant" but
is actually waging a constant war with the host, constantly re-infecting the
lungs. Provided that the host is healthy, it has the upper hand and usually
keeps the TB in check - LTBI. TB is particularly tricky to eliminate as it
can be either replicating, when it can be killed by the antibiotics, or
non-replicating when antibiotics are useless. The long, nine month course of
antibiotics is needed to ensure that all traces of the non-replicating form
are eliminated from the lungs. Further details can be found at
www.archivelfarma.com/hipotesi_an.html

Archivel's novel, two pronged approach combines a one month
course of antibiotic to eliminate the bacteria in the replicating stage and
two injections of the company's RUTI vaccine that stimulates the body's own
immune system to fight the TB bacteria. This combination approach reduces the
treatment time from nine months to one, is easier to manage, less expensive,
more effective and more likely to be done completely. The company estimates
that cost comparison between the current and new treatment, when allowing for
all the logistical costs means that the new treatment costs around half that
of the old treatment.

Further information at
www.archivelfarma.com/noticies_an.html

Full details can be found in the accompanying press release
AF004002 entitled "Archivel's RUTI, a novel therapeutic vaccine to Latent
Tuberculosis, starts phase II clinical trials in South Africa" and press
release AF004001 entitled "Major breakthrough in fight to eliminate
Tuberculosis".

Further information on Archivel at www.archivelfarma.com

Archivel Farma S.L., 61 c/ Fogars de Tordera, Poligon
Industrial Bonavista, 08916 BADALONA, Spain. Tel +34-93-497-2456,
+34-637-057432, ORue@archivelfarma.com

Press information and illustrations

Nigel Robson, Vortex PR, Tel +44(0)1481-233080, nigel@vortexpr.com

RUTI is a registered trademark of Archivel Farma S.L.

Press information and illustrations: Nigel Robson, Vortex PR, Tel +44(0)1481-233080, nigel at vortexpr.com; RUTI is a registered trademark of Archivel Farma S.L..